{Reference Type}: Case Reports
{Title}: Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.
{Author}: Lundy J;McKay O;Croagh D;Ganju V;
{Journal}: JCO Precis Oncol
{Volume}: 6
{Issue}: 0
{Year}: 01 2022
{Factor}: 5.479
{DOI}: 10.1200/PO.21.00437
{Abstract}: